Johnson & Johnson

Selected news for the company - Johnson & Johnson, collected since 10/2017. There are 77.2K items in the archive. This company shares news with COVID-19, Pfizer, COVID-19 Vaccine, Moderna, Coronavirus and hundreds of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
6/7/2022 Biotech Stock Arcellx Surges On Plans To Rival Johnson & Johnson In Cancer | Investor's Business Daily investors.com Newcomer Arcellx ( ACLX ) could rival Johnson & Johnson ( JNJ ) in multiple myeloma, an analyst said Monday as the biotech stock soared to a two-month high.X Arcellx tested tailor-made cancer drugs, known as CAR-T, in patients with advanced multiple myeloma. Every patient responded, and all signs of cancer disappeared in 71% of patients who could be evaluated."Pretty much any way you slice the updated data, (Arcellx's treatment's ...
6/7/2022 Johnson & Johnson terminates COVID-19 vaccine contract with Emergent - WSJ newsbreak.com Johnson & Johnson (NYSE:JNJ) has notified Emergent BioSolutions (NYSE:EBS ...
6/7/2022 Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations | Johnson & Johnson jnj.com CHICAGO, ILLINOIS, June 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced initial results from the pivotal Phase 2 RAGNAR study evaluating the investigational use of BALVERSA ® (erdafitinib), a fibroblast growth factor receptor (FGFR) kinase inhibitor, in patients with advanced solid tumors with prespecified FGFR alterations. At a planned interim analysis (IA), responses were observed across a variety of FGFR-driven solid tumors for patients who ...
6/7/2022 Global $11.99 Bn Contact Lens Markets to 2026: Growing Smart Contact Lens Demand / Increased Consolidation of Market Players / Increasing Shift Towards Daily Disposable Lenses PR Newswire DUBLIN , June 7, The "Global Contact Lens Market: Insights & Forecast with Potential Impact of COVID-19 (2022-2026)" report has been added to ResearchAndMarkets.com's offering.The global contact lens market is forecasted to reach US$11.99 billion in 2026, growing at a CAGR of 7% for the period spanning 2022-2026The factors such as increasing spending on eyewear products by population, rising prevalence of myopia, rapid urbanization and improving consumer confidence ...
6/7/2022 Breakthroughs In Treating Killer Diseases Could Lengthen Life PR Newswire ... Therefore, discovering viable treatments for these issues is a worthwhile endeavor that could reduce the economic burden and potentially lengthen life. Here we consider this regarding GlaxoSmithKline Plc (NYSE: GSK ), AstraZeneca Plc (NASDAQ: AZN ), Johnson & Johnson (NYSE: JNJ ), Eli Lilly (NYSE: LLY ), and Cardiol Therapeutics (NASDAQ: CRDL ) (TSX: CRDL).Sadly, the Global Burden of Disease Study, published in October 2020 , suggests that the world might be approaching a turning point ...
6/7/2022 Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations PR Newswire Data from RAGNAR, the largest tumor-agnostic study reported for a targeted therapy and the first to evaluate FGFR-driven malignancies, featured in oral presentation at the 2022 ASCO Annual MeetingCHICAGO , June 7, The Janssen Pharmaceutical Companies of Johnson & Johnson today announced initial results from the pivotal Phase 2 RAGNAR study evaluating the investigational use of BALVERSA ® (erdafitinib), a fibroblast growth factor receptor (FGFR) kinase inhibitor, in patients ...
6/6/2022 How Newcomer Arcellx Is Looking To Rival Johnson & Johnson In Cancer newsbreak.com Newcomer Arcellx (ACLX) could rival Johnson & Johnson (JNJ) in multiple myeloma, an analyst said Monday as the biotech stock soared to a two-month high. Arcellx tested tailor-made cancer drugs, known as CAR-T, in patients with advanced multiple myeloma. Every patient responded, and all signs of cancer disappeared in 71% of ...
6/6/2022 Social Media Specialist - Ethicon - Johnson & Johnson - Redwood City, CA haceonline.org eMarketingSiloSocial Media Specialist - EthiconDescription Robotics & Digital Solutions, part of the Johnson & Johnson family of companies, is recruiting for a Social Media Specialist located in Redwood City, CA.Robotics & Digital Solutions is part of Ethicon, Inc., a global leader in surgery with products and solutions found in almost every operating room around the world. Ethicon has made significant contributions to surgery for more than 100 years from creating the ...
6/6/2022 Serotiny Announces a Research Collaboration With Janssen to Optimize Designs for Chimeric Antigen Receptors Signaling Domains | VentureBeat VentureBeat ... Äì(BUSINESS WIRE)‚ÄìJune 6, 2022‚ÄìSerotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering, announced today a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson , to optimize CAR designs for cellular therapy. The collaboration will leverage Serotiny‚Äôs tMDP mining and design capabilities with Janssen‚Äôs antibody development and cell therapy expertise to create next generation CAR-based cell ...
6/5/2022 Updated Data for Janssen's Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma PR Newswire ... the BCMAxCD3 bispecific antibody, including progression-free survival and subgroup analysesData from MajesTEC-1 study published in The New England Journal of MedicineJune 5, 2022 , CHICAGO /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab Phase 1/2 MajesTEC-1 study. Teclistamab is an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA), which is ...
6/5/2022 Updated Data for Janssen's Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma | Johnson & Johnson jnj.com CHICAGO, ILLINOIS, June 5, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab Phase 1/2 MajesTEC-1 study. Teclistamab is an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA), which is being studied in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy. 1 The ...
6/5/2022 Johnson & Johnson (NYSE:JNJ) Shares Sold by Cigna Investments Inc. New dispatchtribunal.com Cigna Investments Inc. New lowered its stake in Johnson & Johnson ( NYSE:JNJ – Get Rating ) by 26.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,771 shares of the company’s stock after selling 21,123 shares during the period. Johnson & Johnson comprises 0.8% of Cigna Investments Inc. New’s investment portfolio, making the stock its 17th ...
6/5/2022 Cigna Investments Inc. New Cuts Stake in Johnson & Johnson (NYSE:JNJ) theenterpriseleader.com Cigna Investments Inc. New trimmed its position in shares of Johnson & Johnson ( NYSE:JNJ – Get Rating ) by 26.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 59,771 shares of the company’s stock after selling 21,123 shares during the quarter. Johnson & Johnson comprises about 0.8% of Cigna Investments Inc. New’s holdings, making the stock its 17th biggest holding. Cigna ...
6/5/2022 Updated Data for Janssen's Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma | Business Wire Business Wire BEERSE, Belgium- The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab Phase 1/2 MajesTEC-1 study. 1 Teclistamab is an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA), which is being studied in patients with relapsed or refractory multiple myeloma (RRMM). 1 The data were featured as part of an oral session during the 2022 American ...
6/4/2022 Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI‚Ñ¢ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma PR Newswire At nearly 28 months of median follow-up, median progression-free survival and overall survival were not yet reached Data presented at the 2022 ASCO Annual Meeting and published in the Journal of Clinical OncologyCHICAGO The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b /2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI‚Ñ¢ (ciltacabtagene autoleucel; cilta-cel), a B-cell ...
6/3/2022 Phase 3 SHINE Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma PR Newswire Primary results from the first frontline Phase 3 study of a Bruton's tyrosine kinase inhibitor in MCL to be presented as late-breaking data at the 2022 ASCO Annual Meeting and also published in The New England Journal of MedicineCHICAGO The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the Phase 3 SHINE study ( Abstract 7502 ), which demonstrated that the combination of once-daily oral IMBRUVICA ...
6/3/2022 Phase 3 SHINE Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma | Johnson & Johnson jnj.com CHICAGO, ILLINOIS, June 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the Phase 3 SHINE study ( Abstract 7502 ), which demonstrated that the combination of once-daily oral IMBRUVICA ® (ibrutinib) plus bendamustine-rituximab (BR) and rituximab maintenance significantly reduced the risk of disease progression or death by 25 percent compared to patients who received placebo plus BR and rituximab maintenance in patients aged ...
6/3/2022 Global Contact Lens Market Insights & Forecasts Report 2022-2026 Featuring Key Players - Johnson & Johnson, Alcon, The Cooper Companies, Bausch Health, Hoya, & ST. Shine Optical - ResearchAndMarkets.com | Business Wire Business Wire DUBLIN--( BUSINESS WIRE )--The "Global Contact Lens Market: Insights & Forecast with Potential Impact of COVID-19 (2022-2026)" report has been added to ResearchAndMarkets.com's offering.The global contact lens market is forecasted to reach US$11.99 billion in 2026, growing at a CAGR of 7% for the period spanning 2022-2026The factors such as increasing spending on eyewear products by population, rising prevalence of myopia, rapid urbanization and improving consumer confidence ...
6/1/2022 New Data Show Patients Treated with First-in-Class TREMFYA® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years | Johnson & Johnson jnj.com SPRING HOUSE, PENNSYLVANIA, June 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with TREMFYA ® (guselkumab) achieved consistent, long-term efficacy through two years across the domains of active psoriatic arthritis (PsA) – including joint, skin, enthesitis, a dactylitis, b spinal pain and disease severity c endpoints – irrespective of baseline characteristics. 1 Further analyses showed TREMFYA ...
6/1/2022 Global PDO Thread Lift Market Research Report 2022 | Johnson & Johnson, Medtronic blogspot.com ... domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.Global key manufacturers of PDO Thread Lift include Johnson & Johnson, Medtronic, Sinclair Pharma, Croma-Pharma, and Corza Medical, etc. In terms of revenue, the global top four players hold a share over % in 2021.Get Free Sample or Customize Request at: https://www.globalinforesearch.com/reports ...